OP2 Organizational Impact Model Associated With Switching From Intravenous (IV) to Subcutaneous (SC)

CONTEXT: A new formulation of natalizumab subcutaneous has been recently authorized in highly active relapsing remitting multiple sclerosis (RRMS), offering two routes of administration for individual patient needs (SC and IV). This new presentation might enhance convenience to patients and HCP ’s by saving hospital resources and patient time.
Source: Value in Health - Category: International Medicine & Public Health Authors: Source Type: research